BRUSSELS - The European Medicines Agency (EMA) stressed on Tuesday (16 March) that the benefits of AstraZeneca's Covid-19 vaccine continue to outweigh the risks - after a dozen member states suspended its use in national inoculation programmes over blood-clot concerns.
"A situation like this is not unexpected when you vaccinate millions of people. Our role is to evaluate these so we can figure out is this a real side effect or is it a coincidence," EMA executive director Emer Cooke told a news conference.
